<code id='5CF1EDF585'></code><style id='5CF1EDF585'></style>
    • <acronym id='5CF1EDF585'></acronym>
      <center id='5CF1EDF585'><center id='5CF1EDF585'><tfoot id='5CF1EDF585'></tfoot></center><abbr id='5CF1EDF585'><dir id='5CF1EDF585'><tfoot id='5CF1EDF585'></tfoot><noframes id='5CF1EDF585'>

    • <optgroup id='5CF1EDF585'><strike id='5CF1EDF585'><sup id='5CF1EDF585'></sup></strike><code id='5CF1EDF585'></code></optgroup>
        1. <b id='5CF1EDF585'><label id='5CF1EDF585'><select id='5CF1EDF585'><dt id='5CF1EDF585'><span id='5CF1EDF585'></span></dt></select></label></b><u id='5CF1EDF585'></u>
          <i id='5CF1EDF585'><strike id='5CF1EDF585'><tt id='5CF1EDF585'><pre id='5CF1EDF585'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:893
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Health insurers' Q3 question: how much care are people getting?
          Health insurers' Q3 question: how much care are people getting?

          AdobeHealthcareprovidersandhealthinsurancecompaniesareclosingthebooksontheirthirdquarters,andonemajo

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          Amylyx ALS drug fails large clinical trial

          JustinKlee(left)andJoshuaCohenaretheco-foundersandco-CEOsofAmylyxPharmaceuticals.KayanaSzymczakforST